Stryker Co. (NYSE:SYK) Receives Consensus Rating of “Moderate Buy” from Analysts

Stryker Co. (NYSE:SYK) has been assigned an average recommendation of “Moderate Buy” from the thirteen analysts that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $340.45.

SYK has been the subject of several research reports. Evercore ISI increased their price objective on Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Roth Mkm increased their price objective on Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and raised their target price for the stock from $315.00 to $360.00 in a research report on Wednesday, January 31st. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Finally, Wells Fargo & Company raised their target price on Stryker from $336.00 to $364.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 31st.

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 3,273 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the transaction, the director now owns 14,242 shares in the company, valued at $4,856,522. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Allan C. Golston sold 3,273 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the transaction, the director now owns 14,242 shares in the company, valued at approximately $4,856,522. The disclosure for this sale can be found here. Insiders sold a total of 212,109 shares of company stock worth $72,845,768 over the last three months. 5.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Stryker

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Keybank National Association OH lifted its holdings in shares of Stryker by 3.5% during the 3rd quarter. Keybank National Association OH now owns 27,823 shares of the medical technology company’s stock valued at $7,603,000 after purchasing an additional 952 shares in the last quarter. Carnegie Capital Asset Management LLC lifted its holdings in shares of Stryker by 0.5% during the 4th quarter. Carnegie Capital Asset Management LLC now owns 96,241 shares of the medical technology company’s stock valued at $28,820,000 after purchasing an additional 497 shares in the last quarter. CoreCap Advisors LLC lifted its holdings in shares of Stryker by 3.9% during the 4th quarter. CoreCap Advisors LLC now owns 5,030 shares of the medical technology company’s stock valued at $1,506,000 after purchasing an additional 191 shares in the last quarter. DNB Asset Management AS lifted its holdings in shares of Stryker by 5.7% during the 4th quarter. DNB Asset Management AS now owns 76,413 shares of the medical technology company’s stock valued at $22,883,000 after purchasing an additional 4,143 shares in the last quarter. Finally, LGT Capital Partners LTD. lifted its holdings in shares of Stryker by 24.4% during the 4th quarter. LGT Capital Partners LTD. now owns 434,997 shares of the medical technology company’s stock valued at $130,264,000 after purchasing an additional 85,240 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.7 %

Shares of SYK stock opened at $327.68 on Tuesday. Stryker has a 12 month low of $249.98 and a 12 month high of $361.41. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $349.74 and its two-hundred day moving average is $313.59. The company has a market cap of $124.67 billion, a PE ratio of 39.72, a price-to-earnings-growth ratio of 2.62 and a beta of 0.89.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, beating the consensus estimate of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter last year, the company posted $3.00 earnings per share. The company’s revenue for the quarter was up 11.8% compared to the same quarter last year. Equities analysts predict that Stryker will post 11.86 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a $0.80 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a yield of 0.98%. Stryker’s payout ratio is 38.79%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.